|Bid||114.01 x 800|
|Ask||114.04 x 1100|
|Day's Range||111.94 - 114.60|
|52 Week Range||106.11 - 160.84|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019|
|Forward Dividend & Yield||1.56 (1.33%)|
|1y Target Est||138.46|
McKesson Corporation (MCK) today announced that Kirk Kaminsky will be the new president of McKesson’s U.S. Pharmaceutical and Specialty Solutions (USPSS) business. Kaminsky will assume the role effective immediately, reporting to CEO Brian Tyler. Kaminsky currently serves as president of McKesson Specialty Provider Organization, a division of USPSS, where he leads a team responsible for a broad suite of provider solutions.
While gurus hold positions in these companies, the share price and returns continue to fall. The company, which produces crude oil and natural gas, has a $75.32 billion market cap. The share price of $66 is 17.06% below its 52-week high and 17.27% above its 52-week low.
McKesson Corporation (MCK) will release financial results for its fourth quarter ended March 31, 2019 on Wednesday, May 8, 2019, prior to the opening of trading on the New York Stock Exchange. The company has scheduled a conference call for 8:00 AM Eastern Time (5:00 AM Pacific Time), during which Brian Tyler, chief executive officer, and Britt Vitalone, executive vice president and chief financial officer, will review these results. Holly Weiss, senior vice president, Investor Relations is the leader of the call and the password is ‘McKesson’.
On the basis of the continued decline of pharmaceutical spending growth and external shock threats, we have lowered our economic moat ratings for AmerisourceBergen ABC , Cardinal Health CAH , and McKesson MCK to narrow from wide with a negative trend. The role of pharmaceutical distributor continues to evolve in an increasingly competitive and highly regulated environment. Scale and regulatory requirements have provided insulation to maintain share and generate market returns, but competitive pressures continue to build with declining reimbursement, healthcare consolidation, and decline in overall pharmaceutical spending growth.
The opioid crisis in the United States is a medical and societal tragedy, but some companies are working to fight addiction.
Is McKesson Corporation (NYSE:MCK) a great stock to buy now? The best stock pickers are becoming more optimistic. The number of long hedge fund positions inched up by 2 in recent months. Our calculations also showed that MCK isn't among the 30 most popular stocks among hedge funds. MCK was in 44 hedge funds' portfolios at the […]
NEW YORK (AP) — New York is suing the billionaire family behind the company that created OxyContin, joining a growing list of state and local governments seeking to hold not only the firm but its owners accountable for the nation's opioid crisis.
Cardinal Health and McKesson Corporation have similar business models, but they are very different stocks. This is the case with McKesson and Cardinal Health, as well. McKesson is the more attractive stock for growth, while Cardinal Health is a high-yielding income stock.
The Bay Area exodus is sparking a feeding frenzy among other states willing to write big checks to win Bay Area companies' headquarters and expansion projects.
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
McKesson Corp NYSE:MCKView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for MCK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MCK. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MCK had net inflows of $4.73 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. MCK credit default swap spreads are rising towards their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SQN Investors, which threatened Yelp with a proxy fight and prompted it to move on a number of its recommendations, is now calling on the company to take this cost-cutting action.
The recent loss of two San Francisco Bay Area Fortune 500 headquarters to Texas raises a key question: Who's next?
McKesson Corporation (NYSE:MCK), a large-cap worth US$24b, comes to mind for investors seeking a strong and reliable stock investment. Market participants who are conscious of risk tend to search forRead More...
Warren Buffett said a key factor in corporate site selection should be a state or city's unfunded public pension liabilities.
Pharmaceutical distribution stocks should continue to benefit from an aging population and specialty drugs. Here are three industry leaders to watch.
Texas' pitch to startups: There's low taxes, lots of space and plenty of workers for fast-growing companies to scale up quickly.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.